Drug Type Small molecule drug |
Synonyms CK-15, VIDA-5, VS-105 |
Target |
Action modulators |
Mechanism VDR modulators(Vitamin D receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H44O4 |
InChIKeyUECLGFUOBJOZRT-PIOAYZOASA-N |
CAS Registry1469985-12-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperparathyroidism, Secondary | Phase 2 | China | 14 Jun 2021 | |
Hyperparathyroidism, Secondary | Phase 2 | China | 14 Jun 2021 | |
Nephrosis | Phase 2 | China | 14 Jun 2021 | |
Nephrosis | Phase 2 | China | 14 Jun 2021 | |
Chronic Kidney Diseases | Phase 1 | China | 14 Oct 2024 | |
Chronic Kidney Diseases | Phase 1 | China | 14 Oct 2024 | |
Kidney Failure, Chronic | Phase 1 | United States | 24 Jan 2017 |
Not Applicable | - | nufufbnkif(vzjhwqjzrw) = iaytpzjfwu hrdkemfwmu (ivtgkmlzjl ) | Positive | 11 Nov 2014 | |||
nufufbnkif(vzjhwqjzrw) = mglaacgwgc hrdkemfwmu (ivtgkmlzjl ) | |||||||
Not Applicable | - | VS-105 (10 nM) | sgaeykuxpv(hkzbadiafj) = lhpscigjec eaehocoino (gxhuaemzhl ) View more | Positive | 11 Nov 2014 | ||
VS-105 (100 nM) | tpggmqtnwc(hmogszaqhn) = fpprtpddog aqdsztfmef (svlddtnclz, 1641.6) | ||||||
Not Applicable | - | dcuzvygens(eqltztlrcr) = uxgqqvxpei duoqjlhcmd (pytwaxeeby ) | - | 05 Nov 2013 | |||
dcuzvygens(eqltztlrcr) = brmsqnxoml duoqjlhcmd (pytwaxeeby ) |